Literature DB >> 1717267

A second pathway of activation of the Torpedo acetylcholine receptor channel.

K O Okonjo1, J Kuhlmann, A Maelicke.   

Abstract

We have studied the interaction of the reversible acetylcholine esterase inhibitor (-)physostigmine (D-eserine) with the nicotinic acetylcholine receptor (nAChR) from Torpedo marmorata electric tissue by means of ligand-induced ion flux into nAChR-rich membrane vesicles and of equilibrium binding. We find that (-) physostigmine induces cation flux (and also binds to the receptor) even in the presence of saturating concentrations of antagonists of acetylcholine, such as D-tubocurarine, alpha-bungarotoxin or antibody WF6. The direct action on the acetylcholine receptor is not affected by removal of the methylcarbamate function from the drug and thus is not due to carbamylation of the receptor. Antibodies FK1 and benzoquinonium antagonize channel activation (and binding) of eserine, suggesting that the eserine binding site(s) is separate from, but adjacent to, the acetylcholine binding site at the receptor. In addition to the channel activating site(s) with an affinity of binding in the 50 microM range, there exists a further class of low-affinity (Kd approximately mM) sites from which eserine acts as a direct blocker of the acetylcholine-activated channel. Our results suggest the existence of a second pathway of activation of the nAChR channel.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717267     DOI: 10.1111/j.1432-1033.1991.tb16231.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  12 in total

Review 1.  Functional architecture of the nicotinic acetylcholine receptor: a prototype of ligand-gated ion channels.

Authors:  A Devillers-Thiéry; J L Galzi; J L Eiselé; S Bertrand; D Bertrand; J P Changeux
Journal:  J Membr Biol       Date:  1993-11       Impact factor: 1.843

Review 2.  Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease.

Authors:  William C Motel; Andrew Coop; Christopher W Cunningham
Journal:  Mini Rev Med Chem       Date:  2013-03       Impact factor: 3.862

3.  Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors.

Authors:  Natalia M Kowal; Philip K Ahring; Vivian W Y Liao; Dinesh C Indurti; Benjamin S Harvey; Susan M O'Connor; Mary Chebib; Elin S Olafsdottir; Thomas Balle
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

4.  Barbiturate interactions at the human GABAA receptor: dependence on receptor subunit combination.

Authors:  S A Thompson; P J Whiting; K A Wafford
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

5.  Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on non-alpha-subunit interfaces of heteromeric neuronal nicotinic receptors.

Authors:  Scott B Hansen; Palmer Taylor
Journal:  J Mol Biol       Date:  2007-03-31       Impact factor: 5.469

6.  Photoaffinity labeling of Torpedo acetylcholine receptor at multiple sites.

Authors:  S J Tine; M A Raftery
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

7.  Identification of binding sites in the nicotinic acetylcholine receptor for TDBzl-etomidate, a photoreactive positive allosteric effector.

Authors:  Selvanayagam Nirthanan; Galo Garcia; David C Chiara; S Shaukat Husain; Jonathan B Cohen
Journal:  J Biol Chem       Date:  2008-06-04       Impact factor: 5.157

8.  Activation and block of the adult muscle-type nicotinic receptor by physostigmine: single-channel studies.

Authors:  Julius Militante; Bei-Wen Ma; Gustav Akk; Joe Henry Steinbach
Journal:  Mol Pharmacol       Date:  2008-06-03       Impact factor: 4.436

Review 9.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

10.  Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholinergic action.

Authors:  Qian-Sheng Yu; Marcella Reale; Mohammad A Kamal; Harold W Holloway; Weiming Luo; Kumar Sambamurti; Balmiki Ray; Debomoy K Lahiri; Jack T Rogers; Nigel H Greig
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.